New research suggests that commonly prescribed cholesterol-lowering medicines may also support eye health by being linked to a lower risk of glaucoma and reduced need for laser or surgical treatment.
The findings, published in the British Journal of Ophthalmology, suggest that statins could have effects beyond lowering cholesterol and preventing cardiovascular disease.
“After five years, statin users had a 15% lower observed risk of developing open-angle glaucoma than non-users”
The study does not prove that statins prevent glaucoma, and experts stress that they should not be prescribed solely for eye disease at this stage. Even so, the results add to mounting interest in whether these widely used medicines may help protect the optic nerve.
Glaucoma affects an estimated 95 million people worldwide. It is a leading cause of irreversible blindness and is often called the “thief of sight” because it can develop slowly, without obvious early symptoms. The disease damages the optic nerve, which carries visual information from the eye to the brain. As the damage progresses, people may experience loss of peripheral vision, blurred sight and, in severe cases, blindness.
There is no cure for glaucoma. Treatment is centred on reducing intraocular pressure, the pressure created by fluid inside the eye. Depending on the type and severity of disease, patients may use medicated eye drops, undergo laser therapy, receive minimally invasive glaucoma surgery or require conventional operations. These approaches can slow the condition and protect remaining vision. They cannot restore vision already lost.
The new research examined health data from around 210,000 adults aged over 40 who had used statins. Their outcomes were compared with matched individuals who had never used the medicines. Researchers focused on open-angle glaucoma, the most common form of the disease, as well as the need for procedures intended to control it.
After five years, statin users had a 15% lower observed risk of developing open-angle glaucoma than non-users. At ten years, the difference remained, with a 10% lower risk among people who had used statins.
The study also found lower rates of glaucoma interventions in statin users. At five years, people taking statins had a 36% lower risk of incisional glaucoma surgery, a 55% lower risk of minimally invasive glaucoma surgery and a 60% lower risk of selective laser trabeculoplasty. Selective laser trabeculoplasty, often known as SLT, is a treatment that uses laser energy to improve fluid drainage from the eye.
At ten years, the associations continued. Statin users had a 32% lower risk of incisional surgery, a 46% lower risk of minimally invasive glaucoma surgery and a 51% lower risk of SLT.
The figures are notable, particularly because glaucoma treatment often becomes more intensive as the disease progresses or when eye drops are no longer enough to achieve safe pressure levels. Fewer laser treatments and operations could indicate slower progression, better pressure control or a lower likelihood of needing escalation in care.
However, the results need careful interpretation. The research was observational, meaning it analysed existing health records rather than randomly assigning people to take statins or not. Observational research can reveal important patterns in large populations, but it cannot establish cause and effect.
“Glaucoma affects an estimated 95 million people worldwide. It is a leading cause of irreversible blindness and is often called the “thief of sight” because it can develop slowly, without obvious early symptoms”
People taking statins may differ from non-users in ways that are difficult to capture fully in medical records. They may attend healthcare appointments more frequently, have different levels of cardiovascular risk, use other medicines or follow different lifestyle patterns. These factors could influence glaucoma detection, management or treatment decisions.
Researchers said randomised controlled trials are required to determine whether statins themselves reduce the chance of glaucoma or slow its progression. Such studies would assign comparable groups of people to receive a statin or another treatment, allowing scientists to assess whether the medicine is responsible for any difference in outcomes.
Until that evidence is available, statins should be regarded only as a possible complement to standard glaucoma treatment. They are not a substitute for eye drops, laser procedures, surgery or regular monitoring. People with glaucoma should continue their prescribed treatment plan and speak to their ophthalmologist before making any changes.
Statins are most commonly prescribed to lower low-density lipoprotein cholesterol, or LDL cholesterol. They are used widely to reduce the risk of heart attack and stroke in people with high cholesterol or established cardiovascular disease. Their potential relevance to glaucoma may lie in biological actions that extend beyond cholesterol control.
One theory is that statins may affect pathways involved in the drainage of fluid from the eye. In open-angle glaucoma, fluid may not drain efficiently through the trabecular meshwork, a drainage tissue near the front of the eye. This can raise intraocular pressure and contribute to optic-nerve damage. If statins improve drainage in some way, they might help reduce pressure or make it easier to control.
Another possibility involves neuroprotection. Glaucoma damages the optic nerve through a complex mixture of pressure-related stress, reduced blood supply, inflammation and cell injury. Some research has suggested that statins may have anti-inflammatory or nerve-protective properties. If they help optic-nerve cells withstand injury, they could offer benefit even in people whose eye pressure is already controlled.
Blood-vessel health may be another factor. Glaucoma is not solely a disease of raised eye pressure. Some people develop optic-nerve damage despite pressure readings that fall within the normal range. This form, often called normal-tension glaucoma, may involve blood-flow problems, blood-pressure changes or other vascular influences. Because statins can improve aspects of vascular health, researchers are exploring whether this could help protect the optic nerve.
The results are encouraging because most existing glaucoma treatments focus almost entirely on lowering eye pressure. Pressure control remains essential. Yet specialists recognise that it does not prevent progression in every patient. New treatments aimed at inflammation, blood flow and nerve survival could expand the options available to clinicians.
For now, people should not start a statin simply because they are worried about glaucoma. These medicines are prescribed after a clinician considers cholesterol levels, cardiovascular risk, medical history, potential interactions and possible side effects. Although statins are safe and effective for many people, they are not appropriate for everyone.
For those who already take statins for cardiovascular reasons, the research may provide reassuring evidence of a possible additional benefit. It should not, however, be treated as a guarantee of protection against glaucoma. Regular eye care remains important, especially for people with known risk factors.
Risk rises with age. A family history of glaucoma, diabetes, severe short-sightedness, prolonged steroid use and certain eye conditions can also increase vulnerability. People of African, Asian and Hispanic heritage may have higher risks for particular forms of glaucoma. Comprehensive eye examinations are particularly valuable because the most common form often produces no early warning signs.
Open-angle glaucoma usually develops gradually. By the time someone notices reduced side vision, permanent optic-nerve damage may already have occurred. Eye examinations can assess eye pressure, inspect the optic nerve, test visual fields and measure the thickness of the cornea. These assessments help specialists identify glaucoma before major sight loss develops.
Sudden symptoms require urgent care. Severe eye pain, eye redness, blurred vision, halos around lights, headache, nausea or vomiting can indicate acute angle-closure glaucoma, a medical emergency that needs immediate assessment.
The study offers a promising lead rather than a change in clinical practice. It highlights the value of examining whether established medicines can serve new roles, particularly in diseases where treatment options remain limited. If future randomised trials confirm the association, statins could become part of a broader strategy to reduce glaucoma risk or preserve vision alongside pressure-lowering therapies.
Until then, the message is straightforward. Statins remain medicines for cholesterol management and cardiovascular prevention. Glaucoma treatment remains focused on lowering eye pressure and protecting the optic nerve through established care. The link between the two is scientifically interesting, potentially important and still awaiting confirmation.
The post Use of Cholesterol-Lowering Statins Linked to Lower Glaucoma Risk and Fewer Eye Procedures first appeared on PP Health Malaysia (PPHM) | 10POINTS Evidence-Based Health News.
